Olaptesed pegol
Phase 2Small molecule
Olaptesed pegol is one of 91 small molecule programs targeting Pancreatic Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Olaptesed pegol
TTME Pharma AG
Phase 2
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olaptesed pegol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- TTME Pharma AG